ChromaDex’s (CDXC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of ChromaDex (NASDAQ:CDXC) in a research note released on Monday morning,Benzinga reports. They currently have a $11.00 price target on the stock.

Several other equities analysts also recently issued reports on the stock. StockNews.com downgraded shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 6th. LADENBURG THALM/SH SH boosted their price target on shares of ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a report on Wednesday, March 5th.

ChromaDex Stock Performance

Shares of CDXC opened at $7.94 on Monday. ChromaDex has a 1 year low of $2.31 and a 1 year high of $9.18. The company has a market cap of $617.34 million, a price-to-earnings ratio of 794.79 and a beta of 2.21. The firm has a fifty day moving average of $6.06 and a 200-day moving average of $5.39.

Institutional Investors Weigh In On ChromaDex

Institutional investors have recently bought and sold shares of the stock. USA Financial Formulas acquired a new stake in ChromaDex in the fourth quarter worth about $25,000. State of Wyoming acquired a new stake in ChromaDex in the fourth quarter worth about $39,000. Mercer Global Advisors Inc. ADV acquired a new stake in ChromaDex in the fourth quarter worth about $53,000. Truist Financial Corp bought a new stake in ChromaDex in the fourth quarter worth about $54,000. Finally, FMR LLC bought a new stake in ChromaDex in the third quarter worth about $55,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.